Ali Tafreshi

机构：Massachusetts General Hospital, Topcon (Netherlands) · ORCID：0000-0002-8956-3373

发表论文 141 篇 · 总被引 26737 次 · h-index 35

代表论文

• Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study (2023 · Journal of Clinical Oncology · 被引 557)
• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer (2023 · Journal of Clinical Oncology · 被引 348)
• Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study (2022 · European Urology · 被引 69)
• Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non–Squamous Non–Small Cell Lung Cancer (2022 · Clinical Lung Cancer · 被引 31)
• Association of tranexamic acid with decreased blood loss in patients undergoing laminectomy and fusion with posterior instrumentation: a systematic review and meta-analysis (2021 · Journal of Neurosurgery Spine · 被引 25)
• 974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC) (2022 · Annals of Oncology · 被引 16)